Loading data
LUNGNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 90.5 m USD | 83.79 m USD | 68.68 m USD | 53.66 m USD | 48.42 m USD |
| Cost of revenue | 23.36 m USD | 21.79 m USD | 17.92 m USD | 13.8 m USD | 12.79 m USD |
| Gross profit | 67.14 m USD | 62 m USD | 50.75 m USD | 39.87 m USD | 35.63 m USD |
| Research and development expense | 19.49 m USD | 17.57 m USD | 18.08 m USD | 15.4 m USD | 13.06 m USD |
| Selling, general and administrative expense | 101.31 m USD | 102.14 m USD | 94.61 m USD | 83.11 m USD | 69.87 m USD |
| Operating profit | -53.66 m USD | -57.7 m USD | -61.94 m USD | -58.64 m USD | -47.3 m USD |
| Interest expense | — | — | 3.23 m USD | 1.07 m USD | 829 k USD |
| Profit before tax | -53.38 m USD | -55.89 m USD | -60.27 m USD | -58.57 m USD | -48.32 m USD |
| Income tax expense | 626 k USD | 500 k USD | 571 k USD | 353 k USD | 343 k USD |
| Net income (reported basis) | -54 m USD | -56.39 m USD | -60.84 m USD | -58.92 m USD | -48.66 m USD |
| Net income attributable to common shareholders | -54 m USD | -56.39 m USD | -60.84 m USD | -58.92 m USD | -48.66 m USD |
| Basic earnings per share | -1.33 USD/share | -1.44 USD/share | -1.6 USD/share | -1.59 USD/share | -1.35 USD/share |
| Diluted earnings per share | -1.33 USD/share | -1.44 USD/share | -1.6 USD/share | -1.59 USD/share | -1.35 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.